Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant (NCT03301168)
Phase I/II Study of CaspaCIDeยฎ T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR ฮฑฮฒ+T Cells in Pediatric Patients Affected by Hematological Disorders
๐ฉบ Plain-English Summary (8th-Grade Level)
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Los Angeles โ Los Angeles, California
Age range: 1 Month to 26 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (10 Sites)
- Children's Hospital Los Angeles โ Los Angeles, California
- Stanford University - Division of Pediatric Stem Cell Transplant & Regenerative Medicine โ Palo Alto, California
- Children's National Medical Center โ Washington D.C., District of Columbia
- Children's Healthcare of Atlanta โ Atlanta, Georgia
- Dana-Farber Boston Children's Cancer and Blood Disorders Center โ Boston, Massachusetts
- Children's Hospital at Montefiore โ The Bronx, New York
- Oregon Health Sciences University - Doernbecher Children's Hospital โ Portland, Oregon
- University of Texas Southwestern-Children's Medical Center โ Dallas, Texas
- Baylor College of Medicine/ Texas Children's Hospital โ Houston, Texas
- Fred Hutchinson Cancer Research Center โ Seattle, Washington
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Lymphoblastic Leukemia
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia โ Birmingham, Alabama
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia โ Birmingham, Alabama
- Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia โ Duarte, California
- Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) โ Memphis, Tennessee
- Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy โ Duarte, California
- Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease โ Houston, Texas
Explore by condition: All Acute Lymphoblastic Leukemia clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.